Camber Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Camber Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-725,000	Closed	-$21.9M	–	29
2025 Q1	$21.9M	Buy	725,000 +100,000	+16%	+$3.27M	0.78%	21
2024 Q4	$21.9M	Buy	+625,000	New	+$23.4M	0.51%	29
2024 Q1	–	Sell	-865,000	Closed	-$43.8M	–	39
2023 Q4	$43.8M	Sell	865,000 -1,385,000	-62%	-$66.3M	1.12%	20
2023 Q3	$102M	Sell	2,250,000 -250,000	-10%	-$10.3M	3.36%	13
2023 Q2	$103M	Buy	2,500,000 +575,000	+30%	+$22.1M	3.34%	11
2023 Q1	$68.8M	Hold	1,925,000	–	–	2.12%	16
2022 Q4	$72.7M	Hold	1,925,000	–	–	2.49%	14
2022 Q3	$85.1M	Sell	1,925,000 -775,000	-29%	-$32.7M	2.61%	16
2022 Q2	$100M	Sell	2,700,000 -300,000	-10%	-$11.3M	4.34%	8
2022 Q1	$111M	Buy	3,000,000 +1,610,000	+116%	+$52.7M	4.02%	9
2021 Q4	$42.3M	Sell	1,390,000 -1,110,000	-44%	-$34.9M	1.45%	24
2021 Q3	$83.8M	Buy	2,500,000 +500,000	+25%	+$18.8M	2.58%	19
2021 Q2	$79.8M	Buy	2,000,000 +1,000,000	+100%	+$39.2M	2.69%	17
2021 Q1	$45M	Buy	+1,000,000	New	+$55.8M	1.54%	21

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Camber Capital Management's IONS Position: Q2 2025 in Review

Camber Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2025, closing a stake of 725,000 shares — an estimated $21.9M sold.

Camber Capital Management first reported a position in IONS in Q1 2021 and held it in 14 quarters. The position peaked at $111M in Q1 2022. 362 funds tracked by Wall St. Rank hold IONS as of Q2 2025.

Camber Capital Management reported no remaining Ionis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Camber Capital Management sold 725,000 Ionis Pharmaceuticals shares in Q2 2025, an estimated $21.9M.
Camber Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2021 and held it in 14 quarters.
Camber Capital Management's Ionis Pharmaceuticals position peaked at $111M in Q1 2022.
362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.